3 Medical Instrument Stocks Exploring GenAI to Tackle Industry Woes
GenAI is reshaping medical instruments as Electromed, Globus Medical and Intuitive Surgical navigate M&A and market pressures.
GMED - Globus Medical, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$110.29
DETAILS
HIGH:
$117.00
LOW:
$100.00
MEDIAN:
$112.00
CONSENSUS:
$110.29
UPSIDE:
30.04%
Stock News
Globus Medical Inc (GMED) Shares Surge 5.1% -- What GF Score of 97 Tells Investors
On May 20, 2026, Globus Medical Inc (GMED) shares rose 5.1% today, reaching a current price of $84.03. The stock is trading within a 52-week range of $51.79 to
GMED vs. SONVY: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Instruments stocks have likely encountered both Globus Medical (GMED) and SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to value investors?
Why Globus Medical (GMED) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Highly Ranked Medical Stocks to Buy Now: DVA, GMED, PGNY
These highly ranked medical stocks have been capitalizing on their sales expansion, and their defensive or secular growth profiles could become even more attractive if an economic downturn emerges.
3 Reasons Why Growth Investors Shouldn't Overlook Globus Medical (GMED)
Globus Medical (GMED) could produce exceptional returns because of its solid growth attributes.
Down 13.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Globus Medical (GMED)
The heavy selling pressure might have exhausted for Globus Medical (GMED) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Globus Medical Q1 Earnings Call Highlights
Globus Medical NYSE: GMED reported a strong start to 2026, with first-quarter revenue and earnings rising sharply as the company cited continued momentum in U.S. spine, margin expansion and contributions from its Nevro acquisition.
GMED Stock Rises on Q1 Earnings & Revenue Beat, '26 EPS View Raised
Globus Medical beats Q1 EPS estimates by 22% as revenues rise 27% to $759.9M; margins widen and 2026 EPS outlook up, lifting shares 5.8%.
Globus Medical (GMED) Tops Q1 Earnings and Revenue Estimates
Globus Medical (GMED) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.68 per share a year ago.
Globus Medical, Inc. (GMED) Q1 2026 Earnings Call Transcript
Globus Medical, Inc. (GMED) Q1 2026 Earnings Call Transcript
Compared to Estimates, Globus Medical (GMED) Q1 Earnings: A Look at Key Metrics
The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Globus Medical Reports First Quarter 2026 Results
AUDUBON, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the first quarter ended March 31, 2026.
Globus Medical (GMED) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Get a deeper insight into the potential performance of Globus Medical (GMED) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
New Strong Buy Stocks for May 5th
WKC, VAC, CLAR, CNK and GMED have been added to the Zacks Rank #1 (Strong Buy) List on May 5, 2026.
Madison Small Cap Fund Q1 2026 Portfolio Activity
ICU Medical's new high-volume pump has more connected features, which we believe will drive retention rates and incremental revenue. SiteOne Landscape Supply controls 18% of this $26 billion industry and has been growing revenue at a low double-digit compound annual growth rate over the past several years. Madison Small Cap Fund liquidated its position in Globus Medical after a multi-year period because the company's success drove its market cap to $12B.
GMED vs. IDXX: Which Stock Should Value Investors Buy Now?
Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Idexx Laboratories (IDXX). But which of these two stocks is more attractive to value investors?
Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZBH Q1 Earnings & Revenues Top Estimates, Stock Dips in Pre-Market
Zimmer Biomet tops Q1 EPS and revenue estimates with strong segment growth and margin expansion, yet shares slip 1.8% premarket after results.
Short Interest in Globus Medical, Inc. (NYSE:GMED) Drops By 14.0%
Globus Medical, Inc. (NYSE: GMED - Get Free Report) saw a large decline in short interest during the month of March. As of March 31st, there was short interest totaling 2,831,226 shares, a decline of 14.0% from the March 15th total of 3,293,919 shares. Based on an average daily volume of 991,496 shares, the days-to-cover ratio
Price Targets
Globus Medical price target raised to $117 from $114 at Needham
$117.00
(was $78.77)
Needham
Globus Medical price target lowered to $103 from $104 at Wells Fargo
$103.00
(was $85.08)
Larry Biegelsen
·
Wells Fargo
Globus Medical price target raised to $115 from $105 at Truist
$115.00
(was $94.32)
Richard Newitter
·
Truist Financial
Globus Medical upgraded to Buy from Hold at Needham
$112.00
(was $90.22)
Needham
Globus Medical initiated with a Buy at TD Cowen
$110.00
(was $92.98)
Cowen & Co.
Globus Medical price target raised to $112 from $105 at Canaccord
$112.00
(was $94.62)
Canaccord Genuity
Globus Medical price target raised to $115 from $90 at Piper Sandler
$115.00
(was $90.54)
Matt O'Brien
·
Piper Sandler
Globus Medical price target raised to $100 from $92 at RBC Capital
$100.00
(was $85.79)
Shagun Singh
·
RBC Capital
Globus Medical price target raised to $105 from $90 at Canaccord
$105.00
(was $85.79)
Caitlin Cronin
·
Canaccord Genuity
Globus Medical resumed with a Hold at Stifel
$64.00
(was $63.45)
Thomas Stephan
·
Stifel Nicolaus
Globus Medical price target lowered to $88 from $95 at RBC Capital
$88.00
(was $57.55)
RBC Capital
Morgan Stanley Upgrades Globus Medical (GMED) to Overweight
$100.00
(was $85.52)
Kallum Titchmarsh
·
Morgan Stanley
Globus Medical price target raised to $77 from $75 at BTIG
$77.00
(was $71.73)
Ryan Zimmerman
·
BTIG
Wells Fargo Upgrades Globus Medical (GMED) to Overweight
$78.00
(was $70.53)
Vik Chopra
·
Wells Fargo
Globus Medical price target raised to $71 from $67 at Morgan Stanley
$71.00
(was $71.07)
Drew Ranieri
·
Morgan Stanley
Globus Medical (GMED) PT Raised to $72 at BTIG
$72.00
(was $65.49)
Ryan Zimmerman
·
BTIG
Globus Medical upgraded to Overweight from Neutral at Piper Sandler
$80.00
(was $64.40)
Matt O'Brien
·
Piper Sandler
BTIG Upgrades Globus Medical (GMED) to Buy
$60.00
(was $51.65)
Ryan Zimmerman
·
BTIG
Globus Medical's Untapped Potential Beyond The NUVA Transaction; Analyst Turns Bullish
$61.00
(was $53.04)
Mathew Blackman
·
Stifel Nicolaus
Morgan Stanley Maintains Equal-Weight on Globus Medical, Raises Price Target to $78
$78.00
(was $71.97)
Morgan Stanley